Previous 10 | Next 10 |
- Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer - - Sutro will present data from the Phase 1 dose expansion for luvelta for patients with endometrial cancers as a Mini Oral Se...
2023-06-26 11:00:02 ET Sutro Biopharma, Inc. ( NASDAQ: STRO ) and Blackstone ( BX ) announced Monday a royalty financing collaboration agreement related to future sales of products currently being developed by Vaxcyte ( PCVX ) under a license from Sutro ( STRO ). P...
- Sutro will receive $140 million upfront and is eligible to receive up to an additional $250 million in future milestone payments in exchange for the royalty, or revenue interest, in potential future sales of Vaxcyte’s products - - Transaction provides non-dilutive growth capita...
- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating that FolRα-selected patients, who represent 80% of the patient population, experienced...
SOUTH SAN FRANCISCO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will p...
2023-05-15 10:38:09 ET Sutro Biopharma press release ( NASDAQ: STRO ): Q1 GAAP EPS of -$0.85. Revenue of $12.7M (+115.3% Y/Y). For further details see: Sutro Biopharma GAAP EPS of -$0.85, revenue of $12.7M
- Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with advanced ovarian cancer will be featured as an oral presentation at ASCO 2023 - - As presented at AACR 2023, STRO-003 demonstrated potent anti-tumor activity and immune-modulating prop...
2023-05-03 10:45:32 ET Sutro Biopharma ( NASDAQ: STRO ) and Mersana Therapeutics ( NASDAQ: MRSN ) were among notable gainers in the morning hours Wednesday after rival oncology-focused biotech ImmunoGen ( NASDAQ: IMGN ) reported positive data for its ovarian cancer d...
2023-05-03 08:34:28 ET Aptorum Group ( APM ) +153% . Akanda ( AKAN ) +113% . ImmunoGen ( IMGN ) +96% surges ~95% as ovarian cancer drug Elahere shows survival benefit in confirmatory trial. Kiromic BioPharma, Inc. ( KRBP ) +59% ....
SOUTH SAN FRANCISCO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the Company’s President of Research &...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Barbara Leyman, Ph.D., a...
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - - Patient expansion phase well underway in Phase 2 study of luvelta in combination with be...
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in foll...